CCT will evaluate the effects of this candidate, which is designed as a biothreat countermeasure, on its cellular drug compounds.
ImmuneRegen BioSciences says that it finalized a material transfer agreement with Celgene Cellular Therapeutics (CCT) related to Homspera®, which is designed to be used as countermeasures for bioterrorism threats. Homspera is derived from Substance P, a naturally occurring peptide immunomodulator and homeostatic compound with the dual effect of improving pulmonary function and stimulating the human immune system.
CCT will evaluate the potential impact of Homspera on cellular products in its development pipeline. ImmuneRegen believes that Homspera will modify stem/progenitor cell activity, which would be of value in multiple therapeutic applications of interest to both companies.
Homspera increased the number of white blood cells in circulation following radiation during early preclinical testing, according to ImmuneRegen. This may indicate that Homspera can reduce the body’s recovery time after radiation treatment for cancer or following unintentional radiation exposure in soldiers, industrial workers, or civilians, the firm explains. ImmuneRegen also reports that studies have also indicated Homspera’s effect on the blood-forming tissues in bone marrow and on hematopoietic stem cells.
